High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F

Clinical and Investigative Medicine

Volumn 20, Issue 5, 1997, Pages 308-319

  Rattner, Jerome B ^a   Rees, Jennifer ^a   Whitehead, Clark M ^a   Casiano, Carlos A ^b   Tan, Eng M ^b   Humbel, René L ^c   Conrad, Karsten ^d   Fritzler, Marvin J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; COMPLEMENTARY DNA; PROTEIN; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CENTROMERE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FROZEN SECTION; HEP 2 CELL; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUNG CANCER; MALE; MELANOMA; MOLECULAR CLONING; NEOPLASM; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TONSIL;

ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; CENTROMERE; CHROMOSOMAL PROTEINS, NON-HISTONE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 0030782861     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Earnshaw WC, Rothfield NF. Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromosoma 1985;91:313-22.
2. Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskelton 1993;26:214-26.
3. Casiano CA, Landberg G, Ochs RL, Tan EM. Autoantibodies to a novel cell cycle-regulated protein which accumulates in the nuclear matrix during S phase and localizes to kinetochores and spindle midzone during mitosis. J Cell Sci 1993;106:1045-56.
4. Kingwell B, Rattner JB. Mammalian centromere/kinetochore composition. A 50 kDa antigen is present in the mammalian centromere/kinetochore. Chromosoma 1987;95:403-7.
5. Rattner JB, Rees J, Arnett FC, Reveille JD, Goldstein R, Fritzler MJ. The centromere kinesin-like protein CENP-E. An autoantigen in systemic sclerosis. Arthritis Rheum 1996;39:1355-61.
6. Fritzler MJ. Autoantibodies in scleroderma. J Dermatol 1993;20:257-68.
7. Liao H, Winkfein RJ, Mack G, Rattner JB, Yen TJ. CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis. J Cell Biol 1995;130:507-18.
8. Fritzler MJ, Valencia DW, McCarty GA. Speckled pattern antinuclear antibodies resembling anticentromere antibodies. Arthritis Rheum 1984;27:92-6.
9. Yen TJ, Compton DA, Wise D, Zinkowski RP, Brinkley BR, Earnshaw WC, et al. CENP-E, a novel human centromere-associated protein required for progression from metaphase to anaphase. EMBO J 1991;10:1245-54.
10. Yen TJ, Li G, Schaar BT, Szilak I, Cleveland DW. CENP-E is a putative kinetochore motor that accumulates just before mitosis. Nature 1992;359:536-9.
11. Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmunitv 1995;8:575-86.
12. Rattner JB, Martin L, Waisman DM, Johnstone SA, Fritzler MJ. Autoantibodies to the centrosome (centriole) react with determinants present in the glycolytic enzyme enolase. J Immunol 1991;146:2341-4.
13. Maniatis T, Fritsch EF, Sambrook J. Molecular cloning: a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
14. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-6.
15. Fritzler MJ, Hamel JC, Ochs RL, Chan EKL. Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex. J Exp Med 1993;178:49-62
16. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis for the VAX. Nucleic Acids Res 1984;12:387-95.
17. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
18. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-15.
19. Graus F, Elkon KB, Posner JB. Sensory neuropathy and small cell lung cancer. Antineuronal antibody that also react with the tumor. Am J Med 1986;80:45-52.
20. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative Western blot analysis. Ann Neurol 1990;27:544-52.
21. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody positive patients. Neurology 1992;42:1931-37.
22. Dalmau J, Posner JB. Neurological paraneoplastic syndromes. Springer Semin Immunopathol 1996;18:85-95.
23. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders. At the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA 1996;93:4529-36.
24. Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993;71:26-35.
25. Rattner JB, Hendzel MJ, Furbee CS, Muller MT, Bazett-Jones DP. Topoisomerase II a is associated with the mammalian centromere in a cell cycle- and species-specific manner and is required for proper centromere/kinetochore structure. J Cell Biol 1996;134:1097-107.
26. Imai H, Furuta K, Landberg G, Kiyosawa K, Liu LF, Tan EM. Autoantibody to DNA topoisomerase II in primary liver cancer. Clin Cancer Res 1995;1:417-22.
27. Landberg G, Tan EM. Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells. Exp Cell Res 1994;212:255-61.
28. Muro Y, Chan EKL, Landberg G, Tan EM. A cell cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Comm 1995;207:1029-37.
29. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
30. Davidoff A, Inglehart JD, Marks J. Immune response to p53 is dependent upon p53/HSP70 complexes. Proc Natl Acad Sci U S A 1992;89:3439-42.
31. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
32. Naschitz JE, Rosner I, Rozenbaum M, Elias N, Yeshurun D. Cancer-associated rheumatic disorders: clues to occult neoplasia. Semin Arthritis Rheum 1995;24:231-41.
33. Latham BA, Fernandes L. Paraneoplastic syndromes in patients with ovarian neoplasia. J R Soc Med 1994;87: 368-9.
34. Caldwell DS, McCallum RM. Rheumatologic manifestations of cancer. Med Clin North Am 1986;70:385-417.
35. Tan EM. Autoantibodies in pathology and cell biology. Cell 1991;67:841-2.
36. Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995;16:90-8.
37. Landberg G, Erlanson M, Roos G, Tan EM, Casiano CA. Nuclear autoantigen p330d/CENP-F: a marker for cell proliferation in human malignancies. Cytometry 1996;25:90-8.